TNFRSF8 and T-cell non-Hodgkin lymphoma: Horwitz et al. [22] observed objective responses to brentuximab vedotin in patients with relapsed T-cell lymphomas, and these responses were seen among patients regardless of their CD30 expression status in the tumor samples.